# Impact of CYP2D6 Genetic Polymorphisms on the Vulnerability to Drug-drug Interactions With Tramadol

> **NCT04249674** · — · UNKNOWN · sponsor: **University Hospital, Geneva** · enrollment: 172 (estimated)

## Conditions studied

- Interaction
- Pain

## Interventions

- **DIAGNOSTIC_TEST:** Dextrometorphan
- **GENETIC:** Genotyping by single nulcetoide polymorphism.

## Key facts

- **NCT ID:** NCT04249674
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-04
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-12
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2022-01-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04249674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04249674, "Impact of CYP2D6 Genetic Polymorphisms on the Vulnerability to Drug-drug Interactions With Tramadol". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04249674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*